HKMPF (Hikma Pharmaceuticals) Tariff Resilience Score: 5/10 (As of Jul. 05, 2026)


HKMPF Hikma Pharmaceuticals PLC HKMPF
82 GF Score
Price $20.12
GF Value $27.44
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Hikma Pharmaceuticals Tariff Resilience Score?

Hikma Pharmaceuticals HKMPF 82 Tariff Resilience Score is 5 as of Jul. 05, 2026. GuruFocus rates HKMPF with a GF Score™ of 82/100 and a GF Value™ of $27.44 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,028 Drug Manufacturers companies, Hikma Pharmaceuticals ranks better than 84.53% on this metric.

Hikma Pharmaceuticals has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Hikma Pharmaceuticals has Pharmaceuticals with global supply chain. Vulnerable to tariffs on raw materials and finished products. Mitigation through diversified manufacturing locations and essential product exemptions.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Hikma Pharmaceuticals might have Average Resilient.

Hikma Pharmaceuticals  (OTCPK:HKMPF) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Hikma Pharmaceuticals Tariff Resilience Score Related Terms

HKMPF vs ZTS, UTHR, VTRS: Tariff Resilience Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Hikma Pharmaceuticals's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hikma Pharmaceuticals Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hikma Pharmaceuticals's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Hikma Pharmaceuticals's Tariff Resilience Score falls into.


HKMPF
82GF Score
Hikma Pharmaceuticals PLC HKMPF
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
Hikma Pharmaceuticals (HKMPF) has a Tariff Resilience Score of 5 as of Jul. 05, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Hikma Pharmaceuticals ranks #159 out of 1028 companies in the Drug Manufacturers industry, placing it in the top 15.5%.
Is Hikma Pharmaceuticals' Tariff Resilience Score too high?
Hikma Pharmaceuticals' current Tariff Resilience Score is 5. Based on the distribution chart, Hikma Pharmaceuticals ranks #159 out of 1028 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Hikma Pharmaceuticals has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hikma Pharmaceuticals' Tariff Resilience Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hikma Pharmaceuticals ranks #159 out of 1028 companies for Tariff Resilience Score. This places Hikma Pharmaceuticals in the top 16% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Hikma Pharmaceuticals's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hikma Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hikma Pharmaceuticals (HKMPF) is currently considered Modestly Undervalued. The stock's GF Value™ is $27.44, compared to a current price of $20.12 — trading 26.7% below its estimated fair value. The current Tariff Resilience Score is 5. Hikma Pharmaceuticals' overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Hikma Pharmaceuticals (HKMPF), the current Tariff Resilience Score is 5 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hikma Pharmaceuticals (HKMPF) Overvalued in 2026?

Based on GuruFocus' analysis, Hikma Pharmaceuticals stock appears to be undervalued. The current stock price of $20.12 is trading 26.7% below its estimated GF Value™ of $27.44. GuruFocus considers Hikma Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for HKMPF:

  • Tariff Resilience Score: 5
  • GF Value™: $27.44 vs. price of $20.12 (26.7% below fair value)
  • GF Score™: 82/100 with 5 warning signs

No single metric tells the full story. See the HKMPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hikma Pharmaceuticals Business Description

Address 10 Portman Square, London, GBR, W1H 6AZ
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
82GF Score

Get the complete analysis for HKMPF

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.12
Price
$27.44
GF Value